2016
DOI: 10.18553/jmcp.2016.22.5.516
|View full text |Cite
|
Sign up to set email alerts
|

Defining and Measuring Primary Medication Nonadherence: Development of a Quality Measure

Abstract: No funding was received for this article, and the authors declare no conflicts of interest. The views expressed in this article are those of the authors alone and do not necessarily reflect those of their respective employers. Adams has received grant support from Pfizer for adherence research. Adams and Stolpe were equally involved in all aspects of study design, data collection and interpretation, and manuscript preparation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
43
0
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 40 publications
(45 citation statements)
references
References 36 publications
(14 reference statements)
1
43
0
1
Order By: Relevance
“…To address this, we have presented an extensive list of factors associated with PMN in each of the six chronic diseases that could be useful in identifying patients at risk for PMN to receive timely interventions to keep them adherent to treatment. In addition, we identified factors that contributed to heterogeneity between studies; this highlights the need for future studies to adopt the recommendations by agencies such as ISPOR and the Pharmacy Quality Alliance (PQA) to facilitate comparability across studies.…”
Section: Discussionmentioning
confidence: 99%
“…To address this, we have presented an extensive list of factors associated with PMN in each of the six chronic diseases that could be useful in identifying patients at risk for PMN to receive timely interventions to keep them adherent to treatment. In addition, we identified factors that contributed to heterogeneity between studies; this highlights the need for future studies to adopt the recommendations by agencies such as ISPOR and the Pharmacy Quality Alliance (PQA) to facilitate comparability across studies.…”
Section: Discussionmentioning
confidence: 99%
“…It is an active role, collaboration with the physician with no place for blame; self-motivated decision to adhere the advice and understood self-regulation [6, 7]. Medication non-adherence is dose not taken, irregular dosing and discontinuation medication [8, 9].…”
Section: Introductionmentioning
confidence: 99%
“…To date, studies have used data from pharmacy benefit management companies and claims data sets to define PMN rates across subpopulations and/or medication classes. 1, 2, 6, 18, 19, 2326 Researchers in pediatric studies have calculated PMN rates between 7% and 25%. 2730 To our knowledge, however, an assessment of pediatric PMN rates across an entire region, regardless of clinical setting, medication class, or payer, has not been pursued.…”
mentioning
confidence: 99%